PHVS vs MBX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHVS · Pharvaris$31.28 ▼ 1.20%
MBX · MBX Biosciences$49.55 ▼ 7.23%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHVS +23.2%
- MBX +58.6%
Head to head
| Metric | PHVS | MBX |
|---|---|---|
| Price | $31.28 | $49.55 |
| Change today | ▼ 1.20% | ▼ 7.23% |
| Market cap | $2.21B | $2.46B |
| Return, 3 months | -16.2% | -25.4% |
| Return, year to date | +12.7% | +57.1% |
| Return, 1 year | +26.0% | +83.0% |
| P/E (TTM) | – | – |
| P/B | 7.6 | 5.2 |
| P/E percentile vs own 5y | 10th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -27.7% | -188.7% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -62.8% | -33.7% |
| Analyst target vs. price | +99.6% | +98.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 41 | 41 |
| 30-day volatility | 45.1% | 66.3% |
| Max drawdown, 1 year | -28.6% | -37.6% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MBX is the largest of the group by market value.
- MBX has returned the most over the past year.
- PHVS has been the calmest stock over the last 30 days.